Assessing Response and Loss of Response to Biological Therapies in IBD

  title={Assessing Response and Loss of Response to Biological Therapies in IBD},
  author={H. Yanai and S. Hanauer},
  journal={The American Journal of Gastroenterology},
  • H. Yanai, S. Hanauer
  • Published 2011
  • Medicine
  • The American Journal of Gastroenterology
  • OBJECTIVES:The advent of biological therapies for inflammatory bowel disease (IBD) began in 1998 with the approval of infliximab for the treatment of refractory (to conventional agents) Crohn’s disease (CD). Since then, the indications for anti-tumor necrosis factor-α (anti-TNFα) therapy have increased to include induction and maintenance of clinical responses and remissions for luminal and fistulizing CD, the treatment of children with CD, and the treatment of adults with ulcerative colitis… CONTINUE READING
    242 Citations
    Update on the management of ulcerative colitis.
    • 18
    • Highly Influenced
    Natalizumab in Crohn's disease: past and future areas of applicability
    • 14
    • Highly Influenced
    • PDF
    Management of Crohn’s disease in poor responders to adalimumab
    • 6
    • PDF
    Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
    • 47
    Personalized therapy with TNF-inhibitors in Crohn's disease: optimizing treatment outcomes by monitoring drug levels and anti-drug antibodies.
    • 9
    • Highly Influenced
    • PDF
    Emerging biologics in inflammatory bowel disease
    • 40
    • PDF


    Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab
    • 382
    • PDF
    Certolizumab pegol for the treatment of Crohn’s disease
    • S. Schreiber
    • Medicine
    • Therapeutic advances in gastroenterology
    • 2011
    • 378
    • PDF
    Infliximab for induction and maintenance therapy for ulcerative colitis.
    • 2,207
    • PDF